AAV9-mediated central nervous system–targeted gene delivery via cisterna magna route in mice

Current barriers to the use of adeno-associated virus serotype 9 (AAV9) in clinical trials for treating neurological disorders are its high expression in many off-target tissues such as liver and heart, and lack of cell specificity within the central nervous system (CNS) when using ubiquitous promot...

Descripción completa

Detalles Bibliográficos
Autores principales: Lukashchuk, Vera, Lewis, Katherine E, Coldicott, Ian, Grierson, Andrew J, Azzouz, Mimoun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4756767/
https://www.ncbi.nlm.nih.gov/pubmed/26942208
http://dx.doi.org/10.1038/mtm.2015.55

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4756767/
https://www.ncbi.nlm.nih.gov/pubmed/26942208
http://dx.doi.org/10.1038/mtm.2015.55

Ejemplares similares